On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date


FreeStyle Libre 2 and Dexcom One NTAG CGM position statement - November 2022_FINAL - amended 21.2.23 Recommended for use as per NICE guidance 15/11/2022
Insulin Glargine (Toujeo®) Recommendation Recommended as an option 24/11/2015
Insulin Glargine Biosimilar(Abasaglar®) Recommendation Recommended first line 24/11/2015


i-Port Advance® for use in children and adults with diabetes Recommendation Recommended as an option 07/06/2022
OmniPod® CSII system for diabetes Recommendation Recommended as an option 02/06/2015
Semaglutide (oral) for type 2 diabetes Recommendation Recommended as an option for intensification of treatment, if use of GLP1RA is clinically appropriate, and if an oral option is preferred. 01/09/2020
Teriparatide Biosimilar Recommendation Recommend for the treatment of osteoporosis in postmenopausal women as per NICE TA161 08/12/2020
Teriparatide for atypical bisphosphonate induced fractures Recommendation Not recommended 23/02/2021


North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i) NENC regional SGLT2 top tips v1.2 - NTAG approved March 2023 - update June 2023 Approved by NTAG 21/03/2023


NENC Medication Management for Type 2 Diabetes in Adults Guidelines NENC Regional T2DM Guidelines FINAL - June 2023 Approved by NENC Medicines Subcommittee 20/06/2023